Get the Stockscreener App
8.62
0.69%
-0.06
After Hours:
8.78
0.16
+1.86%
Arcturus Therapeutics Holdings Inc stock is traded at $8.62, with a volume of 390.15K.
It is down -0.69% in the last 24 hours and up +29.04% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$8.68
Open:
$8.75
24h Volume:
390.15K
Relative Volume:
0.79
Market Cap:
$245.01M
Revenue:
$67.22M
Net Income/Loss:
$-65.78M
P/E Ratio:
-3.6117
EPS:
-2.3867
Net Cash Flow:
$-79.02M
1W Performance:
+1.41%
1M Performance:
+29.04%
6M Performance:
-60.04%
1Y Performance:
-18.45%
1-Day Range:
$8.61
$8.925
1-Week Range:
$8.1001
$8.925
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
8.62 | 246.71M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | B. Riley Securities | Buy |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Published on: 2026-04-10 06:58:22 - baoquankhu1.vn
HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT) - MSN
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript - MSN
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT - marketbeat.com
ARCT Stock Price, Quote & Chart | ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) - ChartMill
ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics features Chief Medical Officer in The Bonnell Foundation podcast discussion - Traders Union
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78 - MSN
BTIG Maintains Arcturus Therapeutics Holdings (ARCT) Buy Recommendation - MSN
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics By Investing.com - Investing.com UK
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics - Investing.com
ARCT.O - Reuters
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vanguard disaggregates holdings; reports 0 shares — Arcturus (ARCT) - Stock Titan
New Highs: Is Arcturus Therapeutics Holdings Inc forming a breakout pattern2026 Historical Comparison & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Setups: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Understanding the Setup: (ARCT) and Scalable Risk - Stock Traders Daily
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - MarketBeat
Arcturus Therapeutics at the 38th Annual Roth Conference: Strategic Shift to Rare Diseases - Investing.com Canada
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data - MSN
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial - marketbeat.com
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation - MSN
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
ARCT: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B.Riley initiates Arcturus stock coverage with buy rating on RNA platform - Investing.com
Arcturus Therapeutics stresses importance of phased clinical trials in drug development - Traders Union
Update Recap: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Can Arcturus Therapeutics Holdings Inc sustain its profitabilityMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
The Technical Signals Behind (ARCT) That Institutions Follow - Stock Traders Daily
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - marketbeat.com
Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts - Traders Union
ARCT Should I Buy - Intellectia AI
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):